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Purpose: The preservative benzalkonium chloride (BAK) may adversely affect ocular surface 
health. This study evaluated symptoms of ocular surface disease (OSD) in patients previously 
treated with a BAK-preserved therapy to lower their intraocular pressure, who either continued 
that therapy or switched to a BAK-free therapy.
Methods: Eligible adult patients with ocular hypertension or open-angle glaucoma that had 
been controlled with BAK-preserved latanoprost 0.005% monotherapy (Xalatan®) for at least 
one month and had a score of $ 13 (0 = none, 100 = most severe) on the Ocular Surface Disease 
Index (OSDI) questionnaire were entered into this prospective, double-masked, randomized, 
active-controlled, multicenter trial. By random assignment, patients either continued with 
BAK-preserved latanoprost 0.005% or transitioned to BAK-free travoprost 0.004% (Travatan 
Z® ophthalmic solution). OSDI scores were assessed again after six and 12 weeks.
Results: For the 678 evaluable patients, mean change in OSDI score from baseline to week 
12 favored the travoprost 0.004% BAK-free group, but was not statistically different between 
groups (P = 0.10). When patients with mild OSD at baseline were assessed after 12 weeks, 
the mean OSDI score was significantly lower (P = 0.04) in the BAK-free travoprost 0.004% 
group (score = 11.6 ± 10.8 units) than in the BAK-preserved latanoprost 0.005% group 
(score = 14.4 ± 11.9 units), and a significantly larger percentage (P , 0.01) improved to normal 
OSDI scores in the BAK-free travoprost 0.004% group (62.9% of group) than in the BAK-
preserved latanoprost 0.005% group (47.0% of group). Patients pretreated with BAK-preserved 
latanoprost 0.005% for .24 months were significantly more likely (P = 0.03) to improve to a 
normal OSDI score after 12 weeks if they were switched to BAK-free travoprost 0.004% (47.9% 
of group) than if they remained on BAK-preserved latanoprost 0.005% (33.9% of group).
Conclusions: Switching from BAK-preserved latanoprost 0.005% to BAK-free travoprost 
0.004% yielded significant improvements in symptoms of OSD in patients with glaucoma or 
ocular hypertension.
Keywords: ocular surface, glaucoma, benzalkonium chloride, prostaglandin analog, 
preservative
Introduction
Most of the currently available topical treatments for elevated intraocular pressure 
(IOP), including latanoprost 0.005%, are preserved with benzalkonium chloride 
(BAK).1 Chronic exposure to BAK-preserved IOP-lowering medications has been 
associated with increased frequency of patient-reported symptoms of ocular dis-
comfort, including burning, stinging, foreign body sensation, and dry eye sensa-
tion.2 In vitro, BAK-preserved latanoprost 0.005% and BAK-preserved travoprost 
0.004% are both toxic to ocular cells, whereas BAK-free travoprost 0.004% is not.3 Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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In animal models, BAK-free travoprost 0.004% did not 
affect goblet cell numbers4 or corneal epithelial cells,5,6 
whereas BAK-preserved latanoprost 0.005% was shown to 
cause losses of goblet cells4 as well as pathologic changes 
in the corneal epithelium.5,6 In humans, chronic exposure 
to BAK-preserved topical IOP-lowering medications was 
associated with signs of adverse effects on the ocular 
surface, including instability of the tear film,7–9 reduced 
density of superficial epithelial cells,7 disruption of cor-
neal epithelial barrier function,8 and conjunctival inflam-
mation.9 Adverse reactions induced by BAK-preserved 
medications may be reversible in glaucoma patients who 
are switched to BAK-free medications.2 For these reasons, 
many researchers and clinicians have recommended BAK-
free IOP-lowering medications.1–9
BAK-induced changes may manifest as symptomatic 
ocular surface disease (OSD) in medically treated glaucoma 
patients.10,11 OSD is an umbrella term that includes dry 
eye, lid disease, conjunctivitis, and keratitis.12 Although 
OSD is seen in approximately 15% of the general elderly 
population,13 it has been reported to occur in 48% to 59% 
of patients with medically treated glaucoma.10,11 A higher 
incidence10 and severity11 of OSD has been reported in 
patients who received multiple BAK-preserved treatments 
concomitantly than in patients who were treated with only 
one BAK-preserved treatment. Antihypertensive medica-
tions with alternative preservative systems (other than 
BAK) could help to maintain the long-term ocular surface 
health of patients with glaucoma, and could avoid inducing 
or aggravating OSD.
In a previous large multicenter clinical trial of patients 
with glaucoma who had been previously treated with either 
latanoprost 0.005% or bimatoprost 0.03%, and who needed 
alternative therapy due to tolerability issues, a switch to 
BAK-free travoprost 0.004% resulted in improvement 
in OSD symptoms that were both clinically and statisti-
cally significant, and maintained equal or better control of 
IOP.14 However, that study was not conducted in a parallel, 
randomized, masked fashion. The objective of this current 
multicenter, double-masked, randomized, controlled study 
was to quantify changes in symptoms of OSD after random-
izing patients with open-angle glaucoma or ocular hyperten-
sion who were previously treated with latanoprost 0.005% 
preserved by 0.02% BAK (Xalatan® ophthalmic solution; 
Pfizer Inc., NY) either to remain on BAK-preserved latano-
prost 0.005% or to change to BAK-free travoprost 0.004% 
(Travatan Z® ophthalmic solution; Alcon Laboratories, Inc., 
Fort Worth, TX).
Methods
This was a prospective, double-masked, randomized, active-
controlled clinical trial, conducted at 66 clinics in the US. 
The protocol was approved by the appropriate review 
boards at all participating institutions, and the trial was con-
ducted in accordance with the tenets of the Declaration of 
  Helsinki. All participating patients signed a written informed 
consent form.
general entry criteria
Eligible patients were at least 18 years of age, had ocular 
hypertension or primary open-angle glaucoma (with or 
without pigment dispersion or a pseudoexfoliation com-
ponent), and had IOP that was adequately controlled on 
latanoprost 0.005% monotherapy for at least one month 
prior to enrollment. Adequate IOP control was deter-
mined for each patient by the enrolling investigator, and 
was defined as being both stable and safe for that patient. 
General ocular health exclusion criteria included the fol-
lowing: corneal abnormalities that could prevent accurate 
applanation tonometry; any intraocular surgery or ocular 
trauma within the previous six months; any ocular laser 
surgery within the previous three months; progressive 
retinal or optic nerve disease; severe central visual field 
loss; or visual acuity worse than 0.6 logMAR in either eye. 
Patients were also excluded if they had used any ocular 
medications (other than latanoprost 0.005% or artificial 
tears) within seven days of the screening visit, or if they 
had taken any systemic medication for less than 30 days 
of stable dosing before the screening visit. Women of 
childbearing potential were allowed to participate in the 
trial only if they were not breastfeeding, were not pregnant 
or planning to become pregnant, and were using adequate 
birth control during the study. All patients were required 
to be willing and able to abstain from the use of any other 
topical ophthalmic eye drops, other than assigned study 
medication, for the duration of the study.
Ocular surface entry criteria
Exclusion criteria related to ocular surface health were 
as follows: OSD that had previously been treated with 
punctal plugs, punctal cautery, topical cyclosporine A, or 
topical corticosteroids; suspected or diagnosed Sjögren’s 
syndrome; prior corneal surgery (including keratorefractive 
surgery) within the previous one year; presence or history 
of clinically significant blepharitis within the previous two 
years; any history of other ocular inflammatory disease 
(eg, rosacea that affected the ocular adnexa or herpes Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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simplex virus keratitis); seasonal ocular allergies expected 
within the study period; and any contact lens wear or cor-
ticosteroid use within the 30 days before the screening   
visit.
All potential patients were screened using the Ocular 
Surface Disease Index (OSDI) questionnaire. The OSDI is a 
validated, self-administered instrument for assessing the pres-
ence and severity of OSD symptoms.15 The OSDI question-
naire includes 12 questions about the respondent’s past-week 
experience with ocular symptoms, vision-related functioning, 
and environmental triggers.15,16 Questions assessed whether 
respondents had eyes that felt gritty, painful, sore, or sensitive 
to light; whether they had blurred or poor vision; whether 
they experienced limitations with reading, driving at night, 
watching television, or working with a computer or bank 
machine; and whether their eyes felt uncomfortable in windy 
conditions, in areas with low humidity, or in air-conditioned 
places.16 Response options for each question were “all of the 
time” (score = 4), “most of the time” (score = 3), “half of the 
time” (score = 2), “some of the time” (score = 1), and “none 
of the time” (score = 0).15 Questions about vision-related 
functioning or environmental triggers could also be answered 
with “not applicable”, in which case that question was not 
factored into the final score calculation. The total OSDI score 
was calculated for each patient using the methods described 
by the OSDI originators,15 as follows:
OSDI score=
(sumofscoresforallquestionsanswered)2 5
Totalnumb
×
e erof questionsanswered
The final total OSDI score could range from 0 to 100, with 
the OSDI scores classified as #12 = normal, 13–22 = mild 
OSD, 23–32 = moderate OSD, and $33 = severe OSD.17 To 
be eligible for inclusion in the study, patients were required 
to have an OSDI score of 13 or higher.
All potential patients were screened with corneal fluo-
rescein staining. Corneal fluorescein staining was conducted 
according to each investigator’s standard procedure, using 
their standard staining agent. Each cornea was scored on 
the following scale, which was designed to assess stain-
ing over the entire corneal surface with no specification of 
corneal regions: 0 = absent (no staining), 1 = mild (a few 
punctate regions of staining, but less than 10% coverage of 
the corneal surface), 2 = moderate (10%–50% coverage of 
the corneal surface), or 3 = severe (more than 50% coverage 
of the corneal surface). To be eligible for the study, patients 
were required to have a corneal fluorescein staining score 
of 1 or higher.
enrollment and masked randomization
Patients who met all entry criteria and who reported 
using latanoprost 0.005% on the evening prior to the 
  screening/enrollment visit were invited to participate. At 
the enrollment visit, the informed consent form was signed, 
comprehensive medical and ophthalmic histories were 
obtained, the OSDI questionnaire was completed, and an 
ocular examination was performed (including visual acuity 
determination, slit-lamp inspection of the anterior segment, 
corneal fluorescein staining, Goldmann tonometry, and 
dilated fundus examination). Women of childbearing poten-
tial provided urine samples for pregnancy tests.
The targeted enrollment was approximately 700 patients 
(350 per group) in order to obtain approximately 650 evalu-
able patients (325 per group). Power calculations (using a 
two-sample t-test with two-sided alpha = 0.05) indicated 
that, with 325 patients per treatment group, the study would 
have at least 90% power to detect a difference between treat-
ment groups that was .5 units on the OSDI questionnaire, 
assuming a common standard deviation of 19 units in the 
mean change from baseline OSDI score.
At the completion of the first visit, enrolled patients were 
randomized to an intervention whereby they either continued 
on therapy with BAK-preserved latanoprost 0.005% or were 
transitioned to therapy with BAK-free travoprost 0.004% 
ophthalmic solution. BAK-preserved latanoprost 0.005% was 
the commercially available Xalatan® ophthalmic solution, 
which is preserved using 0.02% BAK. BAK-free travoprost 
0.004% was the commercially available Travatan Z® ophthal-
mic solution containing the proprietary sofZia® preservative, 
which is an ionic buffer system containing borate, propylene 
glycol, sorbitol, and zinc chloride.
If both eyes met all of the eligibility criteria, both eyes 
were treated with the same test medication; otherwise, only 
the eligible eye was treated. At the study site, the enrolling 
clinician assigned a number to the patient, and then called 
an interactive voice response system that was hosted by the 
study sponsor in order to receive a kit number. These kit 
numbers had been randomized by the study sponsor using 
statistical software (SAS Institute, Cary, NC). The patient 
received the assigned kit of study medication. Within the 
kits, all medications (whether BAK-preserved latanoprost 
0.005% or BAK-free travoprost 0.004%) were packaged 
in identical oval 4 mL polypropylene dropper bottles. Each 
patient received two bottles of the assigned study medication 
and was instructed to instill one drop of study medication 
in the study eye(s) once daily in the evening. In case of a 
medical emergency that required information about the study Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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medication, the investigator or a designee could request 
unmasking of the test medication by calling the interactive 
voice response system.
Efficacy and safety assessments
Patients returned six weeks (42 ± 7 days) after enrollment 
for the second study visit, and 12 weeks (90 ± 7 days) after 
enrollment for the third study visit. Both of these visits 
were scheduled at approximately the same time of day as 
the entry visit for each patient. At both follow-up visits, 
an interval medical history was obtained and any adverse 
events were assessed, the OSDI questionnaire was com-
pleted, and an ocular examination was conducted, consist-
ing of visual acuity, slit-lamp anterior segment inspection, 
corneal fluorescein staining, and Goldmann tonometry. 
At the 12-week visit, a dilated fundus examination was 
conducted, and women of childbearing potential provided 
urine samples for pregnancy tests.
The primary efficacy variable was the mean change 
in OSDI scores between the entry visit and the 12-week 
follow-up visit. A secondary efficacy variable was the per-
centage of patients with a corneal fluorescein staining score 
of 0. Exploratory efficacy variables that were assessed at 
the 12-week follow-up visit were the proportion of patients 
who had a normal OSDI score (#12 units), percentage 
of patients with a $10-point improvement from baseline 
OSDI score, OSDI outcomes stratified by duration of pre-
treatment with BAK-preserved latanoprost 0.005% before 
entering the study, and OSDI outcomes stratified by sever-
ity of baseline OSDI (mild, moderate, or severe). Safety 
variable assessments included best-corrected visual acuity, 
slit lamp evaluations, IOP, dilated fundus examinations, 
and adverse events.
statistical analysis
Continuous variables were assessed using a two-sample t-test 
with two-sided α = 0.05, and categoric variables were assessed 
by Chi-square test with α = 0.05. The null hypothesis stated 
that no relationship existed between BAK-preserved treatment 
and change in OSDI score. The alternative hypotheses stated 
that BAK-preserved latanoprost 0.005% had an adverse impact 
on OSD, which might accrue over a longer duration of BAK-
preserved latanoprost 0.005% treatment, but might be reversible 
to some degree by transition to BAK-free travoprost 0.004%, 
especially in patients with mild OSDI. Unless otherwise speci-
fied, outcome values are presented as mean ± standard deviation 
in text, and as mean ± standard error in figures.
Results
Baseline clinical and demographic data
A total of 724 patients were enrolled, 678 of whom were 
evaluable for the intent-to-treat (ITT) analysis. Four of the 
ITT patients had normal OSDI scores at baseline, which was 
an exclusion criterion, but they received study medication and 
thus were evaluated with the rest of the population. As shown 
in Table 1, the two treatment groups were statistically similar 
(all P . 0.05) in the baseline parameters of gender, age, 
OSDI category, and duration of exposure to BAK-preserved 
latanoprost 0.005% before entry into the study. The first visit 
of the first patient was in July 2008, and the final analysis 
date was in June 2009. Participant flow through the study is 
shown in Figure 1.
Mean change in OsDi scores
For the patients who had mild OSD at baseline, the mean 
OSDI score at the 12-week time point was significantly lower 
(P = 0.04) in patients randomized to BAK-free travoprost 
0.004% (11.6 ± 10.8 units) than in patients who continued 
on BAK-preserved latanoprost 0.005% (14.4 ± 11.9 units), 
as shown in Figure 2. For the overall cohort of patients with 
all baseline OSDI scores, mean OSDI scores at the 12-week 
Table 1 Baseline values and demographics for the intent-to-treat 
population
Travoprost  
0.004% BAK-free,  
n = 343
BAK-preserved 
latanopros 
0.005%, n = 335
Overall  
population 
n = 678
Age, n (%)
18–64 years 131 (38.2%) 114 (34.0%) 245 (36.1%)
$65 years 212 (61.8%) 221 (66.0%) 433 (63.9%)
Gender, n (%)
Male 132 (38.5%) 105 (31.3%) 237 (35.0%)
Female 211 (61.5%) 230 (68.5%) 441 (65.0%)
OSDI category, n (%)
normal* 2 (0.6%) 2 (0.6%) 4 (0.6%)
Mild 141 (41.1%) 136 (40.6%) 277 (40.9%)
Moderate 91 (26.5%) 85 (25.4%) 176 (26.0%)
severe 109 (31.8%) 112 (33.4%) 221 (32.6%)
Duration of BAK-preserved latanoprost pretreatment, n (%)
Total with  
data available†
311 (90.7%) 300 (89.6%) 611 (90.1%)
Without  
data available
32 (9.3%) 35 (10.4%) 67 (9.9%)
1–6 months 109 (31.8%) 100 (29.9%) 209 (30.8%)
6–24 months 78 (22.7%) 87 (26.0%) 165 (24.3%)
.24 months 124 (36.2%) 113 (33.7%) 237 (35.0%)
Notes: *These patients were enrolled due to an error in calculating the baseline 
OsDi score; †Of those patients who could recall their start date with BAK-preserved 
latanoprost 0.005%.
Abbreviations: OsDi, Ocular surface Disease index; BAK, benzalkonium chloride.Clinical Ophthalmology 2010:4
20
15
10
5
0
024
Time, weeks
N
o
r
m
a
l
,
0
 
t
o
 
1
2
M
i
l
d
 
O
S
D
,
>
1
2
 
t
o
 
2
2
M
e
a
n
 
O
S
D
I
 
s
c
o
r
e
68 10
*
travoprost 0.004%
BAK-free
BAK-preserved
latanoprost 0.005%
12
Figure 2 Mean scores on the OsDi questionnaire for the patients who had mild 
OsD at baseline. error bars represent standard error of the mean. *P , 0.05. in the 
BAK-free travoprost group, patient numbers were 141 at baseline, 135 at week 6, 
and 140 at week 12. in the BAK-preserved latanoprost group, patient numbers were 
136 at baseline, 134 at week 6, and 132 at week 12. 
Abbreviations: BAK, benzalkonium chloride: OsDi, Ocular surface Disease index; 
OsD, ocular surface disease.
N = 678 enrolled
BAK-preserved
latanoprost
0.005%
group
travoprost
0.004%
BAK-free
group
Total
n = 335
allocated
Total
n = 343
allocated
n = 21 discontinued, for
reasons that included
adverse events (n = 12),
protocol violation (n = 6),
lost to follow-up (n = 1),
other (n = 1), or
noncompliance (n = 1)
n = 35 discontinued, for
reasons that included
adverse events (n = 10),
protocol violation (n = 9),
lost to follow-up (n = 7),
other (n = 3), or
noncompliance (n = 2)
n = 333 analyzed
after 6 weeks
n = 339 analyzed
after 12 weeks
n = 328 analyzed
after 12 weeks
n = 328 analyzed
after 6 weeks
Randomization
Figure  1  Participant  flow  through  the  study.  When  possible,  patients  who 
discontinued treatment were analyzed before exiting the study, so discontinuation 
and analysis numbers are not mutually exclusive. 
Abbreviation: BAK, benzalkonium chloride.
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time point were not statistically different between the groups, 
ie, 18.4 ± 16.0 for 339 patients in the BAK-free travoprost 
0.004% group, and 19.4 ± 15.3 for 328 patients in the BAK-
preserved latanoprost 0.005% group.
When normalized to baseline values, the mean change 
in OSDI score from the entry visit to the 12-week follow-up 
visit was not significantly larger (P = 0.10) for the patients 
with mild OSD at baseline who were randomized to BAK-free 
  travoprost 0.004% (−5.0 ± 10.8 units, n = 140) than for patients 
with mild OSD at baseline who continued on BAK-preserved 
latanoprost 0.005% (−2.7 ± 12.1 units, n = 132), as shown in 
Figure 3. The mean change from baseline mild OSDI score to 
score at week 12 was statistically different, from zero change 
in both treatment groups (P = 0.01 in the BAK-preserved 
latanoprost 0.005% group and P , 0.0001 in the BAK-free 
travoprost 0.004% group). Mean change from baseline OSDI 
scores in the “baseline–moderate” and   “baseline–severe” 
groups were not statistically different between the treatment 
groups. For the overall cohort of patients with all baseline 
OSDI scores, mean changes in OSDI scores at the 12-week 
time point were not statistically different between groups 
(−11.3 ± 17.2 for the 339 patients in the BAK-free travoprost 
0.004% group and −11.4 ± 17.4 for the 328 patients in the 
BAK-preserved latanoprost 0.005% group).
Patients improving  
to normal OsDi scores
The percentage of patients who had mild OSDI scores at base-
line and who improved to normal OSDI scores after 12 weeks 
was significantly larger (P , 0.01) in the BAK-free travoprost 
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Figure 3 Mean change from baseline scores on the OsDi questionnaire for the 
patients  who  had  mild  ocular  surface  disease  at  baseline.  error  bars  represent 
standard error of the mean.
Abbreviations: BAK, benzalkonium chloride; OsDi, Ocular surface Disease index.Clinical Ophthalmology 2010:4
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0.004% group (62.9% of group, 88 of 140) than in the BAK-
preserved latanoprost 0.005% group (47.0% of group, 62 
of 132), as shown in Figure 4. Percentages of those patients 
who had started at “baseline–moderate” or “baseline–severe” 
OSDI scores and who improved to normal OSDI scores at 
12 weeks were not significantly different between the treat-
ment groups. For the overall cohort of patients with all base-
line OSDI scores, the percentage of patients who improved 
to normal OSDI scores after 12 weeks was not significantly 
different between groups, ie, 41.6% of patients (141 of 339) 
in the BAK-free travoprost 0.004% group, and 38.4% of 
patients (126 of 328) in the BAK-preserved latanoprost 
0.005% group.
Outcomes stratified by duration  
of pretreatment
Of the evaluable population, 611 patients could recall 
how long they had been pretreated with BAK-preserved 
latanoprost before entering the study. Prior exposure to 
BAK-preserved latanoprost was stratified as .24 months in 
35.0% of patients (237 of 678), 6–24 months in 24.3% of 
patients (165 of 678), 1–6 months in 30.8% of patients (209 
of 678), and of unknown duration in 9.9% of patients (67 
of 678), as shown in Table 1. Regardless of baseline OSDI 
score, patients who were pretreated with BAK-preserved 
latanoprost 0.005% for .24 months before entering the 
study were significantly more likely (P = 0.03) to improve to 
a normal OSDI score after 12 weeks if they were switched to 
BAK-free travoprost 0.004% (47.9% of patients, 58 of 121) 
than if they remained on BAK-preserved latanoprost 0.005% 
(33.9% of patients, 37 of 109), as shown in Figure 5. The 
percentage of patients improving to a normal OSDI score 
was not significantly different between the treatment groups 
for patients who were exposed to BAK-preserved latanoprost 
0.005% for 1–6 months or for 6–24 months prior to entry 
into the study.
Patients with $10 point  
improvement in OsDi scores
The percentage of patients who improved $10 points in 
OSDI scores from baseline to week 12 was not statistically 
different between the treatment groups for the overall cohort, 
or for the subgroups of patients with mild, moderate, or 
severe baseline OSDI scores. For the overall population, 
an improvement of $10 points was observed in 53.4% of 
patients (181 of 339) in the BAK-free travoprost 0.004% 
group and in 51.8% of patients (170 of 328) in the BAK-
preserved latanoprost 0.005% group.
Absence of corneal staining
The percentage of patients without corneal staining at week 
12 was not statistically different between treatment groups Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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for the overall cohort, or for the subgroups of patients with 
mild, moderate, or severe baseline OSDI scores. For the 
overall population, absence of corneal staining at week 12 was 
observed in 37.1% of patients (127 of 342) in the BAK-free 
travoprost 0.004% group and 40.0% of patients (132 of 330) 
in the BAK-preserved latanoprost 0.005% group.
safety assessments
No statistical differences in safety parameters were observed 
between treatment groups. The entire enrolled population, not 
just the ITT population, was assessed for safety parameters. 
The most frequently reported treatment-emergent ocular 
adverse events in both treatment groups were eye irritation, 
hyperemia of the eye, eye pain, eye pruritus, and foreign body 
sensation in the eye, as shown in Table 2.
Discussion
In this randomized, controlled, multicenter, 12-week study 
of 678 glaucoma patients who had been treated with BAK-
preserved latanoprost 0.005% for at least one month prior 
to entry to the study, transitioning to BAK-free travoprost 
0.004% produced significant improvements in symptoms 
of OSD for patients who had mild OSDI scores at baseline 
and for patients who had been exposed to BAK-preserved 
latanoprost 0.005% for more than 24 months prior to entry 
into the study.
For patients with mild OSDI scores at baseline, the mean 
improvement was −5.0 units on the OSDI questionnaire 
for patients who were transitioned to BAK-free travoprost 
0.004%. This value (5.0 units) is clinically relevant, because 
it has been established that the minimum clinically impor-
tant difference in OSDI score is 4.5 units in patients with 
mild or moderate OSD.17 The patients in this study who 
continued on BAK-preserved latanoprost 0.005% had OSDI 
scores that improved by only 2.7 points, which did not meet 
that established minimum clinically important difference 
requirement.
Of patients with mild OSDI scores at baseline, those 
who were transitioned to BAK-free travoprost 0.004% were 
significantly more likely to return to normal OSDI scores at 
week 12 and had significantly lower mean scores on the OSDI 
at week 12, when compared with the patients who remained 
on BAK-preserved latanoprost 0.005%. These outcomes 
confirm the validity of the recommendation to switch to 
BAK-free therapy that has been advocated by researchers 
who have investigated BAK-preserved IOP-lowering medica-
tions in vitro,3,18 in animals,4–6 and in glaucoma patients.7–9,19 
Because reversal of the corneal epithelial cell layer damage in 
glaucoma patients who were treated chronically with BAK-
preserved medications would occur gradually over time, 
patients with moderate or severe OSD may need more than 
the 12 weeks allotted in this study before significant OSD 
improvements could be observed after switching to BAK-
free travoprost 0.004%. Patients with moderate or severe 
OSD may have had more factors influencing their ocular 
surface health than the BAK insult alone; ie, these patients 
may have had underlying dry eye pathology or other factors 
that compounded the effect of BAK. In such cases, removing 
BAK would be helpful, but not sufficient, in ameliorating 
the condition.
Another important finding of this study was that patients 
who had been exposed to BAK-preserved latanoprost 0.005% 
for more than 24 months prior to entry into the study were 
significantly more likely to improve to normal OSDI scores 
if they were transitioned to BAK-free travoprost 0.004% than 
if they remained on BAK-preserved latanoprost 0.005%. The 
same was not true of patients pretreated with BAK-preserved 
latanoprost 0.005% for 24 months or less. These results may 
indicate some cumulative, long-term adverse effect of BAK 
on ocular surface health, as has been suggested by in vitro 
studies demonstrating that BAK has dose-dependent toxic 
effects,20–22 and by animal studies demonstrating that BAK is 
persistent in ocular tissues over time.23 Together, these pre-
clinical studies indicate that long-term buildup of daily doses 
of BAK in glaucoma patients could have dose-dependent 
toxic effects on ocular surface health. Such long-term expo-
sure may be common among patients with glaucoma or ocular 
hypertension: one large-scale epidemiologic study found that 
patients had been medically treated for a median of 3.9 years.2 
For the patients who were exposed to BAK-preserved latano-
prost 0.005% for more than 24 months before entering this 
study, the effects of long-term BAK exposure on OSD were 
reversible within 12 weeks for some patients after switching 
Table 2 Most frequently reported treatment-emergent ocular 
adverse events
BAK-free  
travoprost 0.004%  
n = 362
BAK-preserved 
latanoprost 0.005%
n = 362
eye irritation, n (%) 9 (2.5%) 4 (1.1%)
hyperemia of  
the eye, n (%)
11 (3.0%) 4 (1.1%)
eye pain, n (%) 5 (1.4%) 2 (0.6%)
eye pruritus, n (%) 3 (0.8%) 4 (1.1%)
Foreign body  
sensation in  
eyes, n (%)
2 (0.6%) 4 (1.1%)Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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to BAK-free travoprost 0.004%. Similar reversibility of 
adverse ocular signs and symptoms has been demonstrated 
with therapeutic switches to BAK-free IOP-lowering treat-
ments elsewhere in the literature.2,19
Some of the improvements that were observed in this 
study may be attributable to regression towards the mean, 
to increased familiarity with the OSDI questionnaire, or to 
placebo effects.24 However, such effects seemed to occur 
equally in both treatment groups up to the first follow-up 
visit at week 6, but then separation between groups occurred 
between week 6 and week 12 (see Figure 2). Placebo effects 
may also partly explain the lack of difference between the 
treatment groups in corneal staining (in that case, the pla-
cebo effect would involve the investigators seeing what they 
expected to see). Alternatively, or in addition, the staining 
scale that was used in this study may not have been sensitive 
enough to distinguish changes in staining between the groups, 
and the categories on the staining scale may have been too 
broad. Patient-reported outcomes should be considered to be 
more important than corneal staining in this study, because 
the OSDI questionnaire reflects the patient’s perception of 
their quality of life related to ocular symptoms, and because 
discordance often exists between clinical signs and ocular 
symptoms of OSD in individual patients.25 Overall, the 
improvements in OSDI scores that were observed at week 
12 for patients who were transitioned to BAK-free travoprost 
0.004% can be attributed directly to the change in therapy, 
after most methodologic effects were cancelled out earlier 
in the study (at week 6).
In addition to the way that a placebo effect may have 
increased subjective relief, a washout from a possible 
anesthetic effect of BAK may have increased subjective 
discomfort. An esthesiometry study has demonstrated 
that control groups and preservative-free groups had 
significantly more sensitivity in their corneas than did 
groups of patients who were treated with BAK-preserved 
IOP-lowering therapies;7 ie, BAK may act as an anesthetic, 
and may mask the experience of subjective symptoms 
associated with an underlying pathology. In switching to 
a BAK-free therapy, the loss of this hypoesthetic effect of 
BAK may allow some previously masked discomfort to be 
experienced. As the health of the ocular surface improves 
after a switch to the BAK-free treatment, an anesthetic 
effect would become less useful with time, and especially 
when the long-term benefits of a BAK-free treatment have 
been fully realized.
The findings of this study have important implications 
for the medical management of patients with glaucoma, 
because OSD is common among glaucoma patients,10 and 
because glaucoma patients have identified tolerability issues 
as barriers to compliance with IOP-lowering therapies.26 
In choosing an IOP-lowering medication for glaucoma or 
ocular hypertension, a physician should consider both effi-
cacy and tolerability. The IOP-lowering efficacy is equivalent 
between BAK-free travoprost 0.004% and BAK-preserved 
travoprost 0.004%.27 Therefore, physicians could reasonably 
consider a switch from a BAK-preserved therapy to BAK-
free travoprost 0.004% in patients with ongoing glaucoma 
who have comorbid OSD, or could consider initiating 
  BAK-free travoprost 0.004% in new glaucoma patients who 
are at risk of developing OSD due to use of BAK-preserved 
products.
In summary, this was a randomized, controlled, multicenter, 
12-week study of 678 glaucoma patients who had been treated 
with BAK-preserved latanoprost 0.005% for at least one month 
prior to entry to the study, and the results indicated that tran-
sitioning to BAK-free travoprost 0.004% yielded significant 
improvements in symptoms of OSD for patients who had mild 
OSDI scores at baseline and for patients who had been exposed 
to BAK-preserved latanoprost for more than 24 months prior to 
entry into the study. These observations support the conclusion 
that BAK-free travoprost 0.004% is superior to BAK-preserved 
latanoprost 0.005% in restoring a healthy ocular surface in glau-
coma patients with OSD who require treatment for reduction   
of IOP.
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